Expertise in
8
conditions

Caterina Musolino

Messina, IT 
Expertise in
8
conditions
Messina, IT 

Overview

Caterina Musolino practices practicing medicine in Messina, Italy.

Ms. Musolino is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Polycythemia Vera, Chronic Myelogenous Leukemia (CML), Osteotomy, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 154 peer reviewed articles and participating in 16 clinical trials.

Gender

Female

Locations

Messina, 98121, Italy
Other Locations
Via Consolare Valeria 98125 Messina, Via, 98125, Italy
Bari, Italy
Padova, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas
Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas
Enrollment Status: Completed
Publish Date: August 08, 2025
Intervention Type: Other
CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)
CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Other
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.
Enrollment Status: Completed
Publish Date: April 18, 2025
A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).
A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Procedure
Study Drugs: AOP2014, Acetylsalicylic acid
Study Phase: Phase 2
A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years
A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years
Enrollment Status: Unknown
Publish Date: December 14, 2023
Intervention Type: Drug, Other
Study Drug: BEAM
Study Phase: Phase 3
Observational Study on Number and Outcome of Pregnancy in Childbearing Age Female Patients Treated With Chemotherapy for APL (Studies AIDA 0493, AIDA 2000)
Observational Study on Number and Outcome of Pregnancy in Childbearing Age Female Patients Treated With Chemotherapy for APL (Studies AIDA 0493, AIDA 2000)
Enrollment Status: Completed
Publish Date: October 12, 2022
Geriatric Assessment Adapted Therapy for Ph- ALL Elderly Patients. GIMEMA Protocol LAL1104. EudraCT Code 2005-002156-17
Geriatric Assessment Adapted Therapy for Ph- ALL Elderly Patients. GIMEMA Protocol LAL1104. EudraCT Code 2005-002156-17
Enrollment Status: Completed
Publish Date: October 12, 2022
Intervention Type: Procedure
Study Phase: Phase 2
A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.
A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Drugs: R-CHOP or R-bendamustine, Observation, Maintenance Weekly x4, Ibritumomab Tiuxetan + Maintenance, Standard Maintenance
Study Phase: Phase 3
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415
Enrollment Status: Unknown
Publish Date: January 20, 2022
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib
Study Phase: Phase 4
View 9 Less Clinical Trials

154 Total Publications

Editorial expression of concern: Monocytes and lymphocytes as active participants in the pathogenesis of experimental shock.
Editorial expression of concern: Monocytes and lymphocytes as active participants in the pathogenesis of experimental shock.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: September 06, 2024

Frequently Asked Questions about Caterina Musolino

Is Caterina Musolino a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Caterina Musolino is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Caterina Musolino participate in research or clinical trials?

Yes. Caterina Musolino has published 154 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Caterina Musolino's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Musolino's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile